Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMQ1YU)

• Drug Name: FLUASTERONE Drug Info
• Synonyms: HE-2500; 16alpha-Fluoroandrost-5-en-17-one; 8354

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 133967
  CAS Number: CAS 112859-71-9
  TTD Drug ID: DMMQ1YU

Molecule-Related Drug Atlas

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[4]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[5]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[6]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[7]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[8]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[9]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[10]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[11]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[12]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear receptor unspecific (NR)	TT3V81G	NOUNIPROTAC	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Clinical pipeline report, company report or official report of Aeson Therapeutics. Oct 28, 2002.
• [2] Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002 Jun 14;277(24):21379-88.
• [3] Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Cancer Res. 2002 Jul 1;62(13):3685-90.
• [4] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [5] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [6] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [7] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [8] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [9] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [10] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [11] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [12] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [13] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.